Dr. James M. Wright, MD, PhD, FRCP(C)
James (Jim) Wright obtained his MD from the University of Alberta in 1968, his FRCP(C) in Internal Medicine in 1975 and his Ph.D. in Pharmacology from McGill University in 1976. He is a practicing specialist in Internal Medicine and Clinical Pharmacology. He is also Co-Managing Director of the Therapeutics Initiative, Editor-in-Chief of the Therapeutics Letter and Coordinating Editor of the Cochrane Hypertension Review Group. He sits on the Editorial Boards of PLoS One and the Cochrane Library.
Dr. Wright’s research focuses on issues related to appropriate use of prescription drugs, Clinical Pharmacology, clinical trials, systematic review, meta-analysis and knowledge translation.
Dr. Ken Bassett, MD, PhD
Ken Bassett conducts systematic reviews of the efficacy and safety of new and established drugs, as well as pharmaco-epidemiologic studies of serious adverse events associated with prescription drug therapy in British Columbia. His ongoing research interests are in the systematic review of drug therapy and drug funding policy.
Dr. Thomas Perry Jr., MD, FRCP
Dr. Tom Perry graduated from McGill University Medical School in 1978. He achieved Fellowship in the Royal College of Physicians of Canada, and took additional training at the Karolinska Institute Department of Clinical Pharmacology in Stockholm in 1986 and at UBC until 1989, when he was elected to the Legislative Assembly of British Columbia. He served as Opposition Health Critic from 1989-1991, as Minister for Advanced Education, Training & Technology from 1991-93, and as a government MLA from 1993-96. These experiences alerted him to the importance of getting good value for money in health care, in order to maintain an effective universal health service in Canada.
After returning to clinical medicine in 1996 Tom practiced general internal medicine with sick patients at Delta Hospital, UBC Hospital and Vancouver General Hospital until 2014. He now teaches clinical pharmacology through seminars, lectures and elective student clinical training at UBCH. His outpatient practice focuses on pharmacological treatment of chronic pain and high blood pressure and reduction of pointless or dangerous polypharmacy. He has a special interest in the use of videography to teach students and doctors about drugs and about human pathophysiology.
Tom chairs our Education Working Group, participates in the Drug Assessment Working Group, and is primary author for a number of TI Letters. His other interests include wilderness canoeing and hiking, environmental conservation, peace and social justice issues, music, reading, and his wife (an experienced RN) and two children. One thing he likes especially about working with the Therapeutics Initiative is continuous thinking and learning about medicine and drug therapy, and meeting the smart and dedicated health care colleagues with whom we have the opportunity to teach and learn.
Dr. Vijaya Musini, MD, MSc, MSc
Vijaya Musini has conducted and supervised over 200 systematic reviews and meta-analyses on prescription drug therapy. She is an Editor of the Cochrane Hypertension Review Group and has been actively involved in teaching Cochrane Collaboration systematic review methodology and critical appraisal skills on evidence based drug therapy to undergraduate, graduate, medical students and residents.
Dr. Musini graduated from Mumbai University Medical School in 1982. After completing her rotating internship she joined the Department of Community Medicine in 1984 and graduated with a Diploma in Public Health from Mumbai University Medical School in 1985.
She has worked as a Family Practitioner and as a Medical Officer in primary health care centres in Mumbai, India for several years. She also worked as a research assistant in the Departments of Gynaecology and Obstetrics, and Health Care and Epidemiology, Faculty of Medicine, Kuwait University. She immigrated to Canada in 1996 and graduated with a Masters Degree in Pharmacology and Therapeutics from the University of British Columbia in 2000.
Dr. Casey van Breemen, DVM, MSc, PhD
Cornelis (Casey) van Breemen received his DVM at the Ontario Veterinary College in 1960. He pursued clinical veterinary medicine for one year before enrolling as a graduate student at the University of Alberta where he earned an MSc in Physiology in 1962 and a PhD in Pharmacology in 1965. He subsequently did post-doctorate studies in the Department of Polymer Sciences at the Weizman Institute, Israel and the Department of Physiology at the University of Leicester, UK.
In 1967 he was appointed Assistant Professor in Pharmacology at the University of Florida and in 1969 moved to the University of Miami where he was promoted to Professor of Pharmacology in 1977. In 1993 he was recruited by UBC as Head of the Department of Pharmacology & Therapeutics from where he officially retired in 2002, but continued on his productive research career (over 250 publications) in the area of vascular physiology and pharmacology.
From the early sixties to the present Dr. van Breemen has investigated the signaling systems within blood vessels, both of the endothelium and smooth muscle. At present his laboratory focuses on the critical role of nanodomains resulting from complex membrane ultra-structure in vascular control in health and diseases such as Marfan Syndrome and Diabetes. He has trained many successful graduate students and post-doctorate fellows. He has received several distinctions and awards:
- Established Investigator for the American Heart Association, 1972
- Invited visiting Professor at the University of Louvain, 1972
- Sigma-Xi, University of Miami, Professor of the Year, 1991
- Alexander von Humboldt Foundation Senior, US Scientist Award, 1992
- Distinguished Lecturer, Faculty of Medicine, The University of British Columbia, 1995
- Ciba-Geigy Canada Ltd., Prestigious Award for Outstanding Contributions to Pharmacology in Canada, Pharmacological Society in Canada, Bath, UK, July 1996
- UBC Killam Research Prize for 1997
- Invited distinguished professor at Universidad Complutense, Madrid, Spain
Dr. Lorri Puil, MD, PhD
Dr. Lorri Puil obtained her MD from the University of Toronto and has postgraduate training in internal medicine, hematology and clinical pharmacology. She holds a PhD from the University of Toronto in molecular biology (signal transduction), a field directly applicable to the development and assessment of novel therapeutics such as targeted molecules and biologics.
Dr. Puil has 15 years of experience in conducting systematic reviews and directing multidisciplinary knowledge synthesis teams in the evaluation of health care interventions. She is actively involved in teaching research synthesis methods, the critical appraisal of clinical trials and non-randomized studies, and evidence-based drug therapy to health professionals and students. Dr. Puil’s ongoing research interests are the benefits and harms of prescription drugs, including their molecular effects, and methods to improve the quality of evidence syntheses to support policy and clinical decision making.
Dr. Puil is a senior member of the Drug Assessment Working Group, a contributor to Therapeutic Letters, an Editor of the Cochrane Hypertension Group, and a member of the Cochrane & Campbell Equity Methods Group, which aims to improve the applicability of evidence to diverse populations.
Dr. Barbara Mintzes, BSc, PhD
Barbara Mintzes is a Senior Lecturer in the Faculty of Pharmacy at the University of Sydney, Australia, and an Affiliate Associate Professor with the School of Population and Public Health at UBC. She has worked with the Therapeutics Initiative’s Drug Assessment Working Group to carry out systematic reviews of the effectiveness and safety of new drugs since 1999, and was in the Department of Anesthesiology, Pharmacology and Therapeutics and School of Population and Public Health at UBC until March 2015.
Dr Mintzes researches the effects of drug promotion, including direct-to-consumer advertising of prescription medicines, on prescribing, medicine use and thresholds for disease diagnosis. She co-authored the book, “Sex, Lies and Pharmaceuticals” with Ray Moynihan in 2010.
At the University of Sydney, she works with the Charles Perkins Centre, a multi-disciplinary research centre focusing on obesity, diabetes and cardiovascular disease. She co-leads the Charles Perkins Centre’s Evidence Synthesis Node, and is a member of the Bias and Research Integrity Node. Dr Mintzes holds a doctorate in epidemiology from the University of British Columbia. She has also worked for many years with consumer and women’s health organizations, in Canada and internationally.
In 2014-2016, Barbara Mintzes was a paid expert witness on behalf of plaintiffs in two Canadian class action suits, on cardiovascular risks of testosterone treatment, and on hormone replacement therapy and breast cancer. She has no other conflicts to declare.
Dr. Sarah Burgess, BScPharm, ACPR, PharmD
Sarah Burgess completed her BSc in pharmacy at Dalhousie University in Nova Scotia, her hospital pharmacy residency at London Health Sciences Centre in Ontario and her Doctor of Pharmacy degree from the University of British Columbia. Sarah’s interests include critical appraisal of the biomedical literature, conducting systematic reviews and meta-analyses, evidence-based pharmacy practice and prescribing. She is currently a clinical pharmacist at Queen’s Family Health – a collaborative primary care clinic. She is also involved in teaching critical appraisal skills to undergraduate pharmacy students and is a lecturer for various courses. She coordinates 3rd year critical appraisal series for pharmacy students as well as second year courses. Within the Therapeutics Initiative, Sarah is a member of the Drug Assessment Working Group.
Ciprian Jauca, BA, DBM
Ciprian Jauca studied linguistics at the Babes-Bolyai University in Cluj-Napoca, Romania (major in Romance Languages, minor in Germanistic Studies). In 1991 he earned an International Diploma of Business Management and Intercultural Communication from the University of Osnabruck, Germany. He speaks several languages and has worked as translator and simultaneous interpreter, as well as managing social development projects for non-profit organizations before joining the TI in 1994. He has been the Program Coordinator for the Therapeutics Initiative since its inception in 1994. He created the Therapeutics Initiative website and was its first webmaster from 1996 to 2006. He is involved in the international Cochrane Collaboration and since 2001 he has been the Managing Editor for the Cochrane Hypertension Review Group.
Dr. Aaron Tejani, BSc (Pharm), PharmD
Dr. Aaron M Tejani, is a researcher with the Therapeutics Initiative (co-chair of the Education Working Group and the Drug Assessment Working Group), an editor with the Cochrane Hypertension group, a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation coordinator with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of Pharmacy degree at Creighton University (Omaha, Nebraska).
He is currently a member of the Fraser Health Authority Research Ethics Board and serves as a peer reviewer for several biomedical journals. Dr. Tejani has published scientific papers in peer-reviewed journals (including authoring 11 Cochrane systematic reviews) and presented to healthcare professional groups at local, national, and international conferences. He is particularly interested in teaching healthcare professionals how to critically appraise research publications and systematic reviews on medical interventions. He is the lead author of a number of Therapeutics Letters.
Dr. Colin Dormuth, MSc, ScD
Colin Dormuth has 13 years of experience using administrative health care databases to evaluate pharmaceutical policy changes and physician prescribing behaviour. He has been a member of the Therapeutics Initiative since 1995. His research focuses on drug safety and effectiveness, as well as the design and evaluation of reimbursement policies for prescription drugs. He has training in economic theory, applied econometrics, epidemiology, health services outcome research and biostatistics. Dr. Dormuth holds a Sc.D. and S.M. in epidemiology from Harvard University, an M.A. in economics from the University of Victoria, and a B.A. in economics from the University of Manitoba.
Dr. Stan Bardal, BSc (Pharm), MBA, PhD (Pharmacology)
Dr. Bardal is a pharmacologist and faculty member with the UBC medical undergraduate program (MDUP) and the Division of Medical Sciences, University of Victoria, and is the Pharmacology theme director for the MDUP. He lectures frequently in the MDUP, has experience designing curricula and curricular materials, and is co-authoring a pharmacology textbook that will be published by Elsevier in 2011. His research interests include drug policy and pharmacogenomics, as well as basic science pharmacology research in diabetes and angiogenesis.
Dr. M. Alan Brookhart, PhD
Alan Brookhart is an Associate Professor at the University of North Carolina in the Department of Epidemiology – UNC Gillings School of Global Public Health. His research focuses on the development and application of statistical methods for drug utilization and outcomes research using large, health care claims data files. Areas of particular interest include the use of instrumental variable methods to assess short-term drug exposure effects, model selection strategies for efficient control of confounding, and multilevel analysis of prescription drug use data. He is also involved with the design and analysis of several cluster randomized trials. Dr. Brookhart received his PhD in Biostatistics from the University of California at Berkeley.
Conflict of Interest: Dr. Brookhart has received grant-funded support from Amgen for conducting research but no personal compensation or honoraria.
Greg Carney, BSc
Greg Carney holds a Bachelor of Science degree from the University of Victoria in applied economics. He has a unique skill set which combines business analysis, economics, statistical programming, and epidemiology. Since 1999 he has worked as an economist, business analyst, health researcher, statistician, and epidemiologist. His research focuses on post market pharmaceutical surveillance and pharmaceutical outcomes using large health care utilization databases.
Maud van Breemen, BFA, MFA
Maud graduated from the University of Miami, Florida, USA. She has worked as the graphic design and desktop publisher for the Therapeutics Initiative since 1994. She has also provided assistance during the Drug Therapy Courses.
Dr. Anat Fisher, MD, MHA
Anat Fisher obtained her M.D. degree from the Hebrew University of Jerusalem in Israel. She also has a Master of Health Administration from the Tel Aviv University in Israel. She worked as a family practitioner for many years and managed a Hospital Department in a Managed Health Organization. She is an experienced researcher and an expert in data analysis and trend analysis. She has conducted several systematic reviews on safety and efficacy of new drug therapies and is an author of Cochrane systematic reviews.
Dr. Scott Garrison, MD
Scott Garrison has degrees in engineering physics and medicine, and is currently a PhD candidate at the University of British Columbia in the department of experimental medicine. He has worked in Richmond, BC as a full-time office and hospital-based family physician since 1992 and has been a member of GPAC working groups producing the current BC provincial guidelines for the management of hypertension, stroke and cardiovascular risk reduction. He sits on the Primary Care Advisory Council for the Vancouver Coastal Health Authority and is the President of the Medical Staff for Richmond Hospital. He is also a clinical assistant professor with the UBC Dept of Family Practice and the principle investigator of a clinical trial exploring the role of magnesium in muscle cramping.
Carolyn Green, BHSc(PT), PhD
Carolyn J Green, PhD research interests are organized around providing health care decision makers with research based as well as contextualized research. An active and producer of health technology assessment (HTA) from 1992 she builds on a foundation of research synthesis methodologies, incorporating critical appraisal, meta-analysis, utilization analysis and decision analysis using data from administrative databases, systematic reviews and clinical trials.
Doctoral and postdoctoral training has added health informatics and qualitative research perspectives and approaches to her investigations into how knowledge is used in socio-technical systems. To this end she has used institutional ethnography to map health care practice, management and governance systems in relation to regional health boards as well as chronic disease management systems.
Carolyn has a BHSc(PT) from McMaster, a MSc from the Department of Health Care and Epidemiology at UBC, a PhD in Health Informatics from the University of Victoria, and has completed a CIHR sponsored postdoctoral fellowship in Knowledge Translation at the University of Alberta. She currently contributes to evidence development in British Columbia through a number of innovative research programs.
Dr. Benji Heran, PhD
Balraj (Benji) Heran received a B.Sc. (Hon.) in Physiology at the UBC and joined the TI in 2000. He recently graduated from the Ph.D. program in the Department of Anesthesiology, Pharmacology and Therapeutics, UBC. Under the supervision of Dr. Jim Wright, he conducted two systematic reviews of the dose-related blood pressure lowering efficacy of ACE inhibitors and angiotensin receptor blockers for primary hypertension. He is also a contributing author of a number of systematic reviews and protocols published in the Cochrane Library. From 2003 to 2009 he has served on the editorial team of the Cochrane Collaboration Hypertension Review Group as the Trial Search Co-ordinator, since 2009 has been an Editor with the Cochrane Hypertension Group and a Postdoctoral Research Fellow with the Cochrane Heart Group. He has a keen interest in cardiovascular research.
Yuko Kawasumi, PhD
Yuko has recently joined the PharmacoEpidemiology Working Group as an Epidemiologist. Her primary research interest and training is to investigate the quality of prescription medication use, using the linked health administrative claims databases. She has conducted the investigation in relationship with pharmaceutical policy changes, physician prescribing behaviour, and health system characteristics. Her recent research focus is drug safety and post-market pharmaceutical surveillance. Yuko holds a PhD in Epidemiology from Department of Epidemiology, Biostatistics, and occupational health at McGill University.
Kendra Lawrence, BSN
Kendra Lawrence began conducting research with the Therapeutics Initiative and the Cochrane Collaboration while studying for her BSN. During this time, she saw her clinical practice transform as critical thinking was encouraged and reinforced. A true passion for the evidence was discovered as a result of this opportunity to work and learn with the DAWG. Kendra now holds a firm belief that participation in unbiased, independent research instills greater confidence and depth in the relationship she shares with her patients and colleagues. She currently works as a Registered Nurse in Acute Medicine and Palliative Care, and is the author of two Cochrane reviews in progress.
Tarita Miller, BSc
Tarita holds a Bachelor of Science degree in Health Information Science from the University of Victoria. She has recently joined the PharmacoEpidemiology Group, with previous experience as a research officer and data analyst in pharmaceutical policy and outcomes evaluation.
Richard Morrow, MA
Richard Morrow holds an MA in Economics from the University of Victoria and a BA in English Literature from McGill University. His expertise includes policy analysis, communications, health economics, statistical methods and programming. Since 2004, he has worked as a research analyst in the areas of pharmaceutical policy and post-market drug safety and effectiveness.
Dr. Marco Perez, MD, PhD
Marco Perez obtained his MD degree at the University of Guadalajara, Mexico, in 1991. He completed his specialty in Intensive Care Medicine in 1996. He worked as practicing specialist in an intensive care unit for several years. He obtained his PhD in pharmacology & Therapeutics at the University of British Columbia in 2010, specializing in hypertension and hypertensive emergencies.
During his PhD, he conducted two Cochrane systematic Reviews and a randomized controlled trial. He has also been a contributing author of a number of Systematic reviews published in the Cochrane Library and other peer-review medical Journals. Since 2006 he has served on the editorial team on the Cochrane Collaboration- hypertension division. He has also actively involved with the Therapeutics Initiative in the drug assessment-working group, since 2003; and as a clinical reviewer with the Common Drug Review, since 2007. He has evaluated nearly 20 old and new submissions.
He is currently holding a postdoctoral research fellow at the Institut de la Sante et Recherche Medicale (INSERM) in the Université de Lyon, France, working in an international- French/Canadian-hypertension research project.
Doug Salzwedel, MLIS
Doug Salzwedel has worked as Trials Search Co-ordinator (TSC) for Cochrane Hypertension since June 2009, provided user support for the Cochrane Register of Studies software since November 2011, and been a member of the Cochrane TSC Executive since January 2011. As of 2015, Doug is also a member of Cochrane’s TSC Support Team, providing mentoring and ongoing support to TSCs across Cochrane’s international network. Within the Therapeutics Initiative, he works primarily with the Drug Assessment Working Group and on communications activities.
Doug was previously the TSC for the Cochrane Effective Practice and Organisation of Care (EPOC) Review Group, then based in Ottawa. Prior to that, he worked as a librarian/information specialist, providing instruction on evidence-based medicine and information resources to primary care clinicians in a randomised controlled trial at the Institute of Population Health in Ottawa, Canada. He obtained a Masters of Library and Information Science from the University of Western Ontario in 2001.
Dr. Cait O’Sullivan, BA, BScPh, PharmD
Cait O’Sullivan has a clinical pharmacy background in acute general medicine, residential care, and community practice. She received a Bachelor of Arts from the University of New Brunswick (Honours, Medical Anthropology), a Bachelor of Science in Pharmacy from Dalhousie University, and a Doctor of Pharmacy Degree from the University of Washington. Based in the Comox Valley, she is now part of a team of educators with the B.C. Provincial Academic Detailing (PAD) Service. As a reader of the medical literature, Cait has a particular interest in the drug approval process and clinical practice guideline methodology.
Dr. Michael Walker, BSc (Pharm), PhD
Michael JA Walker received his education in Pharmacology at the undergraduate and graduate level at King’s College, University of London. Subsequently his teaching and research career has been spent in medical colleges at various Universities around the World but most particularly over the last 36 years at the University of British Columbia. He has taught and continues to teach at various levels from the undergraduate science level to post graduate medicine and has experiences teaching pharmacology to such levels at various places around the World.
Michael’s scientific studies have encompassed many areas of pharmacology from a study of marine toxins, to beta receptors, to cardiovascular pharmacology, antiarrhythmics and currently drugs for the treatment of asthma and rhinitis. His research activities has encouraged a natural tendency to globe trotting and speaking at locations around the World. Research activities have resulted in 100 plus journal publications, and related materials, as well as textbooks. Michael maintains a keen overall interest in the effect of drugs in general on the health and welfare of the public.
Conflict of Interest: Dr. Walker owns shares and share options in Verona Pharma plc (London, UK) and and shares in private companies. He is an Emeritus Professor at the University of British Columbia (unpaid) and CEO of Verona Pharma plc (paid). He has received grants from Verona Pharma plc for research activities conducted at UBC. He has received honoraria as a speaker at European Respiratory Society and other meetings, and expenses paid for attendance at other meetings funded by Verona Pharma plc. No funding from any pharmaceutical companies other than Verona Pharma plc, a micropharma drug discovery comapny dedicated to discovering potential drugs arising from academic work at King’s College London and elsewhere.
Gavin Wong, BA BSc
Gavin Wong obtained a Bachelor in Economics at the Ohio State University in 2002, a B.Sc in Allied Medical Professions (Respiratory Therapy) at the Ohio State University in 2006 and a RRT in the National Board for Respiratory Care, USA in 2006. He is an Associate Member of the Canadian Society of Respiratory Therapists and an author of Cochrane systematic reviews with the Cochrane Hypertension Group. He has conducted several systematic reviews and meta-analyses on prescription drug therapy.